Turn Therapeutics Inc. (NASDAQ: TTRX)

Turn Therapeutics is a clinical-stage biopharmaceutical company focused on developing non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases and fungal infections. The company’s lead asset, GX-03, targets moderate-to-severe eczema and onychomycosis, leveraging a proprietary formulation of polyhexanide (PHMB) with demonstrated anti-inflammatory and antimicrobial properties. Turn Therapeutics also explores a thermostable intranasal vaccine platform, though its primary efforts remain centered on dermatology. The company operates with a capital-efficient model, outsourcing manufacturing and leveraging partnerships to advance its pipeline while minimizing fixed costs.

Turn Therapeutics generates revenue through licensing agreements and milestone payments tied to its medical device portfolio. Its historical device clearances, including K183681, K160872, and K171191, have been licensed to commercial partners such as Medline, providing passive income streams. The company also earns royalties from partnerships, including a $1.0 million upfront payment and potential future milestones of up to $69.55 million from MiMedx for the FleX Product. While drug development remains the core focus, these agreements fund clinical progress without requiring significant capital investment.

The company operates through the following segments:

• Dermatology Drug Development: This segment drives the clinical advancement of GX-03 for eczema and onychomycosis. GX-03 is currently in a Phase 2 trial for moderate-to-severe eczema, with topline results expected in mid-2026. The program leverages PHMB’s dual mechanism of action, targeting inflammatory cytokines and microbial burden without systemic absorption. For onychomycosis, GX-03 has shown nail penetration and antifungal activity in preclinical studies, positioning it as a potential alternative to existing topical and oral therapies.

• Medical Device Licensing: This segment monetizes FDA-cleared medical devices through partnerships. Products like K183681, a porous antimicrobial gauze, and K171191, indicated for dermatitis management, have been licensed to Medline and other distributors. These devices provide real-world tolerability data for the GX-03 formula while generating licensing fees and royalties. The company retains rights to explore additional device applications but prioritizes drug development.

• Exploratory Vaccine Platform: This segment focuses on the PermaFusion suspension platform, designed to enhance the stability of live vaccines for intranasal delivery. Early data demonstrated 100% recovery of a live VSV vaccine vector after 14 days at ambient temperature, suggesting potential for needle-free, thermostable vaccines. While still in preclinical stages, this program targets government and military procurement opportunities, with initial applications in influenza.

Turn Therapeutics competes in the dermatology and antifungal markets, where established players dominate with systemic and biologic therapies. Key competitors in eczema include Dupixent (dupilumab), an injectable biologic, and topical JAK inhibitors like Vtama. For onychomycosis, oral terbinafine (Lamisil) and topical efinaconazole (Jublia) lead the market but face limitations in efficacy and safety. Turn Therapeutics differentiates itself through GX-03’s non-systemic, non-biologic approach, which avoids the side effects of steroids, biologics, and oral antifungals. Its proprietary PermaFusion platform also enables superior nail penetration and cytokine modulation, addressing unmet needs in topical therapies. The company’s lean operating model and partnerships further enhance its competitive positioning by reducing development costs and accelerating commercialization.

Turn Therapeutics serves a diverse customer base across its segments. For medical devices, its primary customers include large distributors like Medline and MiMedx, which commercialize products in wound care and dermatology. In drug development, the company targets patients with moderate-to-severe eczema and onychomycosis, particularly those seeking non-steroidal, non-injectable alternatives. Its exploratory vaccine platform aims to supply government agencies, military organizations, and public health entities, such as BARDA and the World Health Organization, with thermostable, needle-free vaccines. The company also collaborates with contract research organizations and manufacturing partners to advance its pipeline.